JWH-116: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:JWH-116}} | |||
== | == Overview == | ||
JWH-116 is | '''JWH-116''' is a synthetic cannabinoid that acts as a potent agonist of the [[cannabinoid receptor]]s. It is part of the [[naphthoylindole]] family of compounds, which are known for their psychoactive properties. JWH-116 was developed in the 1990s by Dr. [[John W. Huffman]] and is primarily used in scientific research to study the [[endocannabinoid system]]. | ||
[[File:JWH-116.png|thumb|right|Chemical structure of JWH-116]] | |||
JWH-116 | |||
== | == Chemical Structure == | ||
JWH-116 is chemically classified as a naphthoylindole, with the full chemical name being 1-pentyl-3-(1-naphthoyl)indole. The structure consists of a naphthalene group attached to an indole core, with a pentyl chain at the nitrogen atom of the indole. This configuration is typical of many synthetic cannabinoids, which are designed to mimic the effects of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of [[cannabis]]. | |||
== | == Pharmacology == | ||
JWH-116 | JWH-116 functions as a full agonist at both the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] cannabinoid receptors. These receptors are part of the [[G protein-coupled receptor]] family and are involved in a variety of physiological processes, including [[pain modulation]], [[appetite regulation]], and [[immune response]]. The binding affinity of JWH-116 to these receptors is similar to that of THC, making it a useful compound for studying the effects of cannabinoids in the body. | ||
== | == Legal Status == | ||
The legal status of JWH-116 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. The compound is often included in legislation targeting synthetic cannabinoids, which are sometimes sold as "legal highs" or "herbal incense." | |||
== Research Applications == | |||
JWH-116 is primarily used in research settings to explore the [[endocannabinoid system]] and its role in various physiological and pathological processes. Studies involving JWH-116 can provide insights into the development of new therapeutic agents targeting cannabinoid receptors, potentially leading to treatments for conditions such as [[chronic pain]], [[multiple sclerosis]], and [[epilepsy]]. | |||
== Safety and Toxicity == | |||
As with many synthetic cannabinoids, the safety profile of JWH-116 is not well-established. The compound can produce a range of effects, including [[euphoria]], [[anxiety]], and [[hallucinations]]. There is also a risk of adverse effects such as [[tachycardia]], [[hypertension]], and [[psychosis]], particularly with high doses or prolonged use. | |||
== Related Pages == | |||
* [[Synthetic cannabinoids]] | * [[Synthetic cannabinoids]] | ||
* [[Cannabinoid receptor]] | * [[Cannabinoid receptor]] | ||
* [[ | * [[John W. Huffman]] | ||
* [[ | * [[Naphthoylindole]] | ||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category: | [[Category:Research chemicals]] | ||
Latest revision as of 03:35, 13 February 2025
Overview[edit]
JWH-116 is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of the naphthoylindole family of compounds, which are known for their psychoactive properties. JWH-116 was developed in the 1990s by Dr. John W. Huffman and is primarily used in scientific research to study the endocannabinoid system.
Chemical Structure[edit]
JWH-116 is chemically classified as a naphthoylindole, with the full chemical name being 1-pentyl-3-(1-naphthoyl)indole. The structure consists of a naphthalene group attached to an indole core, with a pentyl chain at the nitrogen atom of the indole. This configuration is typical of many synthetic cannabinoids, which are designed to mimic the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Pharmacology[edit]
JWH-116 functions as a full agonist at both the CB1 and CB2 cannabinoid receptors. These receptors are part of the G protein-coupled receptor family and are involved in a variety of physiological processes, including pain modulation, appetite regulation, and immune response. The binding affinity of JWH-116 to these receptors is similar to that of THC, making it a useful compound for studying the effects of cannabinoids in the body.
Legal Status[edit]
The legal status of JWH-116 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. The compound is often included in legislation targeting synthetic cannabinoids, which are sometimes sold as "legal highs" or "herbal incense."
Research Applications[edit]
JWH-116 is primarily used in research settings to explore the endocannabinoid system and its role in various physiological and pathological processes. Studies involving JWH-116 can provide insights into the development of new therapeutic agents targeting cannabinoid receptors, potentially leading to treatments for conditions such as chronic pain, multiple sclerosis, and epilepsy.
Safety and Toxicity[edit]
As with many synthetic cannabinoids, the safety profile of JWH-116 is not well-established. The compound can produce a range of effects, including euphoria, anxiety, and hallucinations. There is also a risk of adverse effects such as tachycardia, hypertension, and psychosis, particularly with high doses or prolonged use.
